In CAR T cell therapy, the patient’s own T cells are genetically engineered to eliminate his or her tumor cells. It is a highly innovative, personalized living therapy that has shown impressive results, especially in relapsed or refractory B cell malignancies. However, the therapy is also associated with significant challenges. Two CAR T cell products have been approved by the FDA (2017) and EMA (2018) and many more are under development. “We are at a point now where CAR T cells are part of our armamentarium for cancer,” concluded CAR T pioneer Carl June (USA).
Click on the blocks below to read more about CAR T cell therapy or to view webcasts.